SNOT-22 can be used to effectively assess QOL and differentiate between CRSwNP phenotypes, highlighting a greater burden in N-ERD patients. Biomarker analysis supports the distinct inflammatory profile of N-ERD.
López-Chacón et al. (Tue,) studied this question.